Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan
  
Henlius’ HLX43 is the second most advanced in the class of PD-L1-targeting ADCs globally, after Pfizer's PDL1V. (Shutterstock)

More from Clinical Trials

More from Focus On Asia